acyclovir and Hepatitis--Animal

acyclovir has been researched along with Hepatitis--Animal* in 2 studies

Other Studies

2 other study(ies) available for acyclovir and Hepatitis--Animal

ArticleYear
Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice.
    Intervirology, 1997, Volume: 40, Issue:1

    The animal model of necrotic hepatitis caused by HSV-1 infection in juvenile mice was used to compare the efficacies of the oral antiherpes agents famciclovir (FCV), valaciclovir (VACV) and brivudin (BVDU). The experimental infection allows the measurement of viral replication in the liver by macroscopic lesions and the evaluation of mortality from encephalitis. Mice intravenously inoculated with a highly virulent clinical HSV-1 isolate were orally treated by gavage over a period of 3 days starting on day 2 post infection. The reference drug acyclovir (ACV) was administered subcutaneously. Necrotic hepatitis was significantly (p < 0.01) reduced by treatment with FCV, VACV and ACV at a dose of 50 mg/kg per day divided into 3 doses. No significant effect was achieved with BVDU at 200 mg/kg per day. Treatment with FCV at 50 mg/kg per day, ACV at 100 mg/kg per day, and VACV at 200 mg/kg per day significantly (p < 0.001) decreased mortality in mice. BVDU treatment at 200 mg/kg per day did not reduce mortality but significantly prolonged (p < 0.05) the survival time.

    Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cell Line; Disease Models, Animal; Famciclovir; Hepatitis, Animal; Herpes Zoster; Herpesvirus 1, Human; Liver; Mice; Mice, Inbred BALB C; Valacyclovir; Valine; Viral Plaque Assay; Virus Replication

1997
Antiviral activity of the polybasic anion, suramin and acyclovir in Hepadna virus infection.
    The Journal of antimicrobial chemotherapy, 1986, Volume: 18 Suppl B

    Acyclovir and suramin were examined for their efficacy alone and in combination against duck hepatitis B virus (DHBV) in persistently infected Pekin ducks. In ducks the peak plasma concentration of acyclovir was reached thirty minutes after oral administration. Oral acyclovir and suramin administered intravenously suppressed the replication and production of infectious virions as measured by marked reduction of DNA polymerase activity during treatment. However, rebound of enzyme activity was observed soon after cessation of drug therapy. In contrast, sustained reduction of polymerase activity was attained by combined therapy of acyclovir followed by suramin, demonstrating a significant enhancement of anti-DHBV activity which requires confirmation in a larger experimental study. This report establishes that the duck model is ideal for screening antiviral compounds in treatment of infection with Hepadna viruses.

    Topics: Acyclovir; Animals; Drug Therapy, Combination; Ducks; Hepatitis B; Hepatitis B virus; Hepatitis, Animal; Nucleic Acid Synthesis Inhibitors; Suramin

1986